Clinical trials of daraxonrasib, a brand new pancreatic cancer remedy, have confirmed constructive outcomes by serving to some sufferers dwell nearly twice so long as with normal chemotherapy. The FDA has permitted expanded entry to the drug to sufferers who meet sure standards. NCS’s Jacqueline Howard experiences.